Barry Hart, Ph.D. has over 15 years of pharmaceutical research and development, leadership experience. At large pharmaceutical (Johnson & Johnson, Bayer) and biotech companies (ViroBay, Medivation) Barry has successfully lead efforts to improve the efficiency of pre-clinical research programs. Through the integration of Contract Research Organizations and well designed screening paradigms, multiple development candidates were discovered while reducing time-lines and costs. Barry has been the project leader for pre-clinical programs in the areas of oncology (kinase inhibitors), anti-viral, CNS (anti-depressants), peptidomimetics, porphyrins, gold nanoparticles. In five years of virtual drug discovery and development, Project teams successfully delivered 4 “IND ready” compounds. One compound successfully entered Phase I clinical trials.